Carbamazepine is degraded by the bacterial strain Labrys portucalensis F11 (cas 19340-14-8)
-
Add time:08/02/2019 Source:sciencedirect.com
The occurrence of pharmaceuticals in the environment is a topic of concern. Carbamazepine (CBZ) is a widespread antiepileptic drug and due to its physical-chemical characteristics minimal removal is achieved in conventional water treatments, and thus has been suggested as a molecular marker of wastewater contamination in surface water and groundwater. The present study reports the biotransformation of CBZ by the bacterial strain Labrys portucalensis F11. When supplied as a sole carbon source, a 95.4% biotransformation of 42.69 μM CBZ was achieved in 30 days. In co-metabolism with acetate, complete biotransformation was attained at a faster rate. Following a target approach, the detection and identification of 14 intermediary metabolites was achieved through UPLC-QTOF/MS/MS. Biotransformation of CBZ by the bacterial strain is mostly based on oxidation, loss of -CHNO group and ketone formation reactions; a biotransformation pathway with two routes is proposed. The toxicity of untreated and treated CBZ solutions was assessed using Vibrio Fischeri and Lepidium sativum acute toxicity tests and Toxi-Chromo Test. The presence of CBZ and/or its degradations products in solution resulted in moderate toxic effect on Vibrio Fischeri, whereas the other organisms were not affected. To the best of our knowledge this is the first report that proposes the metabolic degradation pathway of CBZ by a single bacterial strain.
We also recommend Trading Suppliers and Manufacturers of F11 (cas 19340-14-8). Pls Click Website Link as below: cas 19340-14-8 suppliers
Prev:Rational design, synthesis, and structure–activity relationships of 5-amino-1H-pyrazole-4-carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors
Next:Biodegradation of Diclofenac by the bacterial strain Labrys portucalensis F11 (cas 19340-14-8)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Assessing the stoichiometric efficacy of mammalian expressed paraoxonase-1 variant I-F11 (cas 19340-14-8) to afford protection against G-type nerve agents08/10/2019
- Humanization of JAA-F11 (cas 19340-14-8), a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis08/09/2019
- Pseudoginsenoside-F11 (cas 19340-14-8) alleviates cognitive deficits and Alzheimer’s disease-type pathologies in SAMP8 mice08/08/2019
- Enantioselective degradation of ofloxacin and levofloxacin by the bacterial strains Labrys portucalensis F11 (cas 19340-14-8) and Rhodococcus sp. FP108/07/2019
- Preclinical Analysis of JAA-F11 (cas 19340-14-8), a Specific Anti–Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging08/06/2019
- Pseudoginsenoside-F11 (cas 19340-14-8) Protects against Transient Cerebral Ischemia Injury in Rats Involving Repressing Calcium Overload08/05/2019
- Supramolecular host-guest interactions of pseudoginsenoside F11 (cas 19340-14-8) with β- and γ-cyclodextrin: Spectroscopic/spectrometric and computational studies08/04/2019
- Biodegradation of Diclofenac by the bacterial strain Labrys portucalensis F11 (cas 19340-14-8)08/03/2019


